Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akcea Therapeutics Inc.

Division of Ionis Pharmaceuticals Inc.
www.akceatx.com

Latest From Akcea Therapeutics Inc.

Pfizer Reaffirms CV Disease Commitment With Deal For Akcea's ANGPTL3 Drug

Pfizer agreed to pay $250m up front for worldwide rights to a Phase II drug that could target a broad population in cardiovascular disease. Scrip talked to Pfizer's head of internal medicine research about it.

Cardiovascular Deals

Akcea C-Suite Upheaval’s Reasons Unclear, Firm Set To Take In More Ionis Programs

Akcea terminates top three execs while praising their accomplishments in building up the Ionis spinout. Stock finished the trading day down nearly 20%.

Commercial Leadership

What Else Analysts Want To Know About Phase III Data For TMC’s Inclisiran

Looking to be a game-changer with a highly effective LDL-C-lowering agent dosed twice annually, The Medicines Company says inclisiran met efficacy endpoints in a large Phase III study. But observers await fuller data, including safety details.

Clinical Trials Business Strategies

Keeping Track: US FDA Greenlights Two More Novel Drugs, But Smacks Down Golodirsen

The latest drug development news and highlights from our US FDA Performance Tracker.
Approvals Drug Review
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • 1662524
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ionis Pharmaceuticals Inc.
  • Senior Management
  • Damien McDevitt, PhD, Interim CEO
    Michael MacLean, CFO
    Louis St. L O’Dea, MD, CMO
    Kyle Jenne, Chief Commercial Officer
  • Contact Info
  • Akcea Therapeutics Inc.
    Phone: (617) 207-0202
    22 Boston Wharf Rd., 9th Fl.
    Boston, MA 02210
    USA
UsernamePublicRestriction

Register